1. Home
  2. WRAP vs ENGN Comparison

WRAP vs ENGN Comparison

Compare WRAP & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Wrap Technologies Inc.

WRAP

Wrap Technologies Inc.

N/A

Current Price

$1.42

Market Cap

106.5M

Sector

Industrials

ML Signal

N/A

Logo enGene Holdings Inc.

ENGN

enGene Holdings Inc.

N/A

Current Price

$1.74

Market Cap

117.2M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
WRAP
ENGN
Founded
2016
1999
Country
United States
Canada
Employees
N/A
N/A
Industry
Ordnance And Accessories
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
106.5M
117.2M
IPO Year
2017
2023

Fundamental Metrics

Financial Performance
Metric
WRAP
ENGN
Price
$1.42
$1.74
Analyst Decision
Hold
Analyst Count
0
10
Target Price
N/A
★ $3.29
AVG Volume (30 Days)
466.8K
★ 736.5K
Earning Date
11-11-2026
09-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 56.85
EPS
★ N/A
N/A
Revenue
★ $4,672,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 3.66
N/A
52 Week Low
$1.04
$1.40
52 Week High
$3.23
$12.25

Technical Indicators

Market Signals
Indicator
WRAP
ENGN
Relative Strength Index (RSI) 42.89 38.18
Support Level $1.39 $1.70
Resistance Level $1.66 $1.84
Average True Range (ATR) 0.10 0.09
MACD 0.01 -0.03
Stochastic Oscillator 33.33 13.75

Price Performance

Historical Comparison
WRAP
ENGN

About WRAP Wrap Technologies Inc.

Wrap Technologies Inc is a public safety technology and services company that delivers safe and effective policing solutions to law enforcement and security personnel. The firm develops policing solutions to law enforcement and security personnel. Its BolaWRAP 150 Remote Restraint device is a patented, hand-held tool that discharges a Kevlar cord to restrain noncompliant individuals from a range of 10-25 feet. The group operates in the Americas, Europe, the Middle East, Africa and the Asia Pacific.

About ENGN enGene Holdings Inc.

enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.

Share on Social Networks: